Literature DB >> 14652720

11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.

T M Stulnig1, W Waldhäusl.   

Abstract

Obesity and Type 2 diabetes mellitus are associated with abnormal regulation of glucocorticoid metabolism that are highlighted by clinical similarities between the sequelae of insulin resistance and Cushing's syndrome, as well as glucocorticoids' functional antagonism to insulin. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activates functionally inert glucocorticoid precursors (cortisone) to active glucocorticoids (cortisol) within insulin target tissues, such as adipose tissue, thereby regulating local glucocorticoid action. Recent data, mainly from rodents, provide considerable evidence for a causal role of 11beta-HSD1 for the development of visceral obesity and Type 2 diabetes though data in humans are not unequivocal. This review summarizes current evidence on a possible role of 11beta-HSD1 for development of the metabolic syndrome, raising the possibility of novel therapeutic options for the treatment of Type 2 diabetes by inhibition or down-regulation of 11beta-HSD1 activity.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14652720     DOI： 10.1007/s00125-003-1284-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  85 in total

Review 1.  11 beta-Hydroxysteroid dehydrogenase.

Authors:  P M Stewart; Z S Krozowski
Journal:  Vitam Horm       Date:  1999       Impact factor: 3.421

2.  Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.

Authors:  Robert C Andrews; Olive Herlihy; Dawn E W Livingstone; Ruth Andrew; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.

Authors:  F Delaunay; A Khan; A Cintra; B Davani; Z C Ling; A Andersson; C G Ostenson; J Gustafsson; S Efendic; S Okret
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice.

Authors:  H J Harris; Y Kotelevtsev; J J Mullins; J R Seckl; M C Holmes
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

5.  Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.

Authors:  H Vestergaard; P Bratholm; N J Christensen
Journal:  Clin Sci (Lond)       Date:  2001-11       Impact factor: 6.124

6.  Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation.

Authors:  Elizabeth H Rabbitt; Gareth G Lavery; Elizabeth A Walker; Mark S Cooper; Paul M Stewart; Martin Hewison
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

Review 7.  Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome.

Authors:  D N Brindley
Journal:  Int J Obes Relat Metab Disord       Date:  1995-05

8.  Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.

Authors:  B R Walker; J C Campbell; R Fraser; P M Stewart; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1992-12       Impact factor: 3.478

9.  Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasić; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1982-07       Impact factor: 10.122

Review 10.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122
View more
  17 in total

1.  Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects.

Authors:  J Westerbacka; A Cornér; K Kannisto; M Kolak; J Makkonen; E Korsheninnikova; T Nyman; A Hamsten; R M Fisher; H Yki-Järvinen
Journal:  Diabetologia       Date:  2005-12-16       Impact factor: 10.122

2.  Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

Authors:  Zhao-Kui Wan; Eva Chenail; Huan-Qiu Li; Manus Ipek; Jason Xiang; Vipin Suri; Seung Hahm; Joel Bard; Kristine Svenson; Xin Xu; Xianbin Tian; Mengmeng Wang; Xiangping Li; Christian E Johnson; Ariful Qadri; Darrell Panza; Mylene Perreault; Tarek S Mansour; James F Tobin; Eddine Saiah
Journal:  ACS Med Chem Lett       Date:  2012-11-23       Impact factor: 4.345

3.  Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Rita Basu; Christopher J Ramnanan; Tiffany D Farmer; Doss Neal; Melanie Scott; Peer Jacobson; Robert A Rizza; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

4.  Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome.

Authors:  Vince Kornél Grolmusz; Orsolya Dóra Acs; Karolina Feldman-Kovács; Ágnes Szappanos; Balázs Stenczer; Tibor Fekete; György Szendei; Péter Reismann; Károly Rácz; Attila Patócs
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

5.  Hypothalamic-pituitary-adrenal axis function: relative contributions of perceived stress and obesity in women.

Authors:  Noha H Farag; William E Moore; William R Lovallo; Paul J Mills; Srikrishna Khandrika; June E Eichner
Journal:  J Womens Health (Larchmt)       Date:  2008-12       Impact factor: 2.681

6.  In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.

Authors:  J Sutinen; K Kannisto; E Korsheninnikova; T Nyman; E Ehrenborg; R Andrew; D J Wake; A Hamsten; B R Walker; H Yki-Järvinen
Journal:  Diabetologia       Date:  2004-09-29       Impact factor: 10.122

7.  Derivatives of (phenylsulfonamido-methyl)nicotine and (phenylsulfonamido-methyl)thiazole as novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: synthesis and biological activities in vitro.

Authors:  Xu Zhang; Yang Zhou; Yu Shen; Li-li Du; Jun-hua Chen; Ying Leng; Jian-hua Shen
Journal:  Acta Pharmacol Sin       Date:  2009-08-24       Impact factor: 6.150

8.  Association between the metabolic syndrome and serum cortisol in overweight Latino youth.

Authors:  Marc J Weigensberg; Claudia M Toledo-Corral; Michael I Goran
Journal:  J Clin Endocrinol Metab       Date:  2008-02-05       Impact factor: 5.958

9.  Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats.

Authors:  Esben S Buhl; Thomas Korgaard Jensen; Niels Jessen; Betina Elfving; Christian S Buhl; Steen B Kristiansen; Rasmus Pold; Lasse Solskov; Ole Schmitz; Gregers Wegener; Sten Lund; Kitt Falck Petersen
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

10.  Functional changes in adipose tissue in a randomised controlled trial of physical activity.

Authors:  Per Sjögren; Justo Sierra-Johnson; Lena V Kallings; Tommy Cederholm; Maria Kolak; Mats Halldin; Kerstin Brismar; Ulf de Faire; Mai-Lis Hellénius; Rachel M Fisher
Journal:  Lipids Health Dis       Date:  2012-06-21       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.